Health Day News — A 14-day continuous glucose monitoring (CGM) trace added to the Diabetes Control and Complications Trial (DCCT) data showed that glycated hemoglobin, as well as microvascular diabetic complications, were detected in a study published online on January 8. It is said that the disease can be predicted. Diabetes technology and treatment.
Boris P. Kovatchev, Ph.D., of the University of Virginia, Charlottesville, and colleagues investigated the association of CGM indicators with microvascular complications of type 1 diabetes observed during DCCT and established time-to-arrival (TIR) as a marker. For blood sugar control. Virtual CGM traces were added to each participant's original DCCT data using a multi-step machine learning procedure.
The researchers found that TIR (70 to 180 mg/dL), calculated from 14 days of virtual CGM data before each glycated hemoglobin measurement, was associated with the observed differences in glycemic control between the intensive and conventional DCCT groups. , and found TIR >60 percent and <40 percent. percentage of each of these groups. TIR, like glycated hemoglobin, was associated with the risk of development or progression of retinopathy, nephropathy, and neuropathy. TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data.
“We demonstrated a strong association between TIR and the risk of development or progression of retinopathy and the development of microalbuminuria,” the authors wrote.
Several authors disclosed relationships with the biopharmaceutical industry.